ATTR-CM Educational Toolkit
The American Heart Association is leading a national effort to improve the recognition, diagnosis, and management of Transthyretin Amyloid Cardiomyopathy (ATTR-CM). In collaboration with clinicians, scientists, and patient advocates, this initiative seeks to reduce diagnostic delays, strengthen multidisciplinary care, and expand awareness of emerging therapies, including gene-based approaches to cardiovascular disease.
This educational toolkit supports both healthcare professionals and patients/caregivers in navigating the complexities of ATTR-CM. The resources are designed to promote disease awareness and education, early recognition, informed decision-making, and meaningful conversations about clinical trial participation. An accompanying clinician guide equips providers to initiate and support discussions around gene therapy and evolving treatment pathways.
ATTR-CM Educational Materials
Health Care Provider Toolkit
This resource helps clinicians engage patients with conditions like transthyretin amyloid cardiomyopathy (ATTR-CM) in conversations about emerging therapies and research opportunities.
-
Clear explanations – Breaks down the differences between gene editing and gene therapy in simple, relatable terms.
-
Patient support – Offers guidance to address common concerns and foster shared decision-making.
-
Clinical trial insights – Outlines the process, protections, risks, and benefits of participation.
-
Trusted resources – Provides links to AHA guides, ClinicalTrials.gov, and genetic counseling directories for further support.
By combining clear communication with reliable tools, this toolkit empowers patients and caregivers to make informed decisions about their care.
Patient & Caregiver Guide
This guide gives patients and caregivers clear, supportive information about genetic heart conditions like transthyretin amyloid cardiomyopathy (ATTR-CM) and emerging treatments.
-
Easy-to-understand explanations – Breaks down genetic conditions, gene editing, and gene therapy using simple examples.
-
Clinical trial basics – Explains what trials are, how they work, and what to expect during participation.
-
Decision support – Helps patients reflect on personal values and goals when considering trial options.
-
Caregiver resources – Offers guidance for supporting loved ones emotionally, practically, and in conversations with doctors.
-
Trusted tools – Connects readers to AHA resources, ClinicalTrials.gov, and genetic counseling services.
This guide empowers patients and families to feel informed, ask the right questions, and move forward with confidence in their care.
Understanding Clinical Trials
This infographic gives patients and families a clear overview of what clinical trials are and what to expect if you join one.
-
What trials do – Explain how treatments are tested for safety and effectiveness.
-
Step-by-step process – Covers learning about the trial, screening and consent, treatment and monitoring, and what happens afterward.
-
Patient choice – Reinforces that participation is voluntary, and you can leave at any time.
-
Support system – Highlights the role of cardiologists, genetic counselors, and trial coordinators in guiding you through the process.
-
Trusted source – Based on recommendations from the American Heart Association.
This resource helps patients and caregivers feel prepared, informed, and supported when considering trial participation.
Understanding Gene Editing
This short video presents gene editing as a groundbreaking approach to treating genetic diseases by fixing the root cause—mutated DNA.
-
How it works — Explains how gene editing tools like CRISPR can precisely target and correct harmful DNA mutations inside cells.
-
Delivery methods — Highlights different ways these editing tools are delivered to cells within the body.
-
Clinical potential — Emphasizes that as the research continues to evolve, gene editing holds increasing promise for safe and effective therapies in clinical trials.
This video is ideal for introducing patients, families, or website visitors to the fundamentals of gene editing in a clear and engaging way.
| Intellia Therapeutics is proud to support the American Heart Association’s ATTR-CM Awareness and Education. |  |
Disclaimer: The materials are for educational purposes only. The content provided does not constitute an endorsement or instruction by the American Heart Association or the American Stroke Association.